Drug-Eluting Stent Update 2007
Key result
Drug-eluting stents prevent late catch-up restenosis for up to 4 years in humans.
Why the study?
Restenosis remains a major limitation of coronary stenting, with differing long-term tissue responses observed between drug-eluting stents and bare metal stents in humans and animal models.
Do drug-eluting stents prevent long-term restenosis compared to bare metal stents without late catch-up?
Population
Patients and porcine models receiving coronary stents
Comparison
Drug-eluting stents (sirolimus-, paclitaxel-, tacrolimus-eluting) vs bare metal stents
Design
Review
Follow-up
Up to 4 years in humans, more than 6 years for bare metal stents
Authors
Discussion
Loading...
Member takes
Implication
Supports sustained DES efficacy without late catch-up in humans; challenges porcine model translation and leaves longer-term durability open.
Structured PICO
Do drug-eluting stents prevent long-term restenosis compared to bare metal stents without late catch-up?
P
Population
Patients and porcine models receiving coronary stents
E
Exposure
Drug-eluting stents (sirolimus-eluting, paclitaxel-eluting, and tacrolimus-eluting stents)
C
Comparator
Bare metal stents
O
Outcome
Restenosis and neointimal proliferationsurrogate
This review highlights that unlike animal models, humans do not exhibit a late catch-up phenomenon of restenosis up to 4 years after drug-eluting stent implantation.
Cite This Study
Daemen et al. (2007) conducted a review in Restenosis. Drug-eluting stents vs. Bare metal stents was evaluated. Drug-eluting stents do not show late catch-up of restenosis for up to 4 years in humans, contrasting with porcine models where an initial 50% reduction at 30 days was lost by 6 months.